Alluvi, formerly BI 4744, presents a notable development in obesity treatment. This dual agonist targeting both GLP-1 and GIP targets demonstrates impressive results in clinical trials, possibly surpassing current https://socialislife.com/story7605338/alluvi-a-comprehensive-investigation-into-retatrutide-s-prospects